Phillip Goldsborough
Psychiatric/Mental Health · Princess Anne, MDNPI 1750081550
Payments from drug & device makers
Across 66 payments — averaging $20.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$338
- Neurocrine Biosciences, Inc.$298
- Lundbeck LLC$149
- AbbVie$136
- Johnson & Johnson$96
- E.r. Squibb & Sons, L.L.C.$91
- plus $222 from 5 others
What the payments were for
- Food & beverage$1,330100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 17 | $338 |
| Neurocrine Biosciences, Inc. | 15 | $298 |
| Lundbeck LLC | 8 | $149 |
| AbbVie | 6 | $136 |
| Johnson & Johnson | 3 | $96 |
| E.r. Squibb & Sons, L.L.C. | 5 | $91 |
| Teva Pharmaceuticals USA, Inc. | 5 | $84 |
| Alkermes, Inc. | 3 | $57 |
| Axsome Therapeutics, Inc. | 2 | $37 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $31 |
| Collegium Pharmaceutical, Inc. | 1 | $14 |
How this compares
$1,330 in reported general payments places this provider in the 75th percentile of 1,461 psychiatric/mental health providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyvanseLisdexamfetamine Dimesylate | 13 | $5,000 |
| Aripiprazole | 77 | $2,078 |
| Hydroxyzine Hcl | 32 | $1,901 |
| Quetiapine Fumarate | 94 | $1,101 |
| Atomoxetine Hcl | 11 | $1,067 |
| Bupropion XlBupropion Hcl | 30 | $918 |
| Fluoxetine Hcl | 48 | $848 |
| Buspirone Hcl | 38 | $572 |
| Trazodone Hcl | 88 | $512 |
| Oxcarbazepine | 23 | $405 |
| Mirtazapine | 34 | $396 |
| Sertraline Hcl | 57 | $359 |
| Lamotrigine | 52 | $335 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 12 | $324 |
| Risperidone | 35 | $255 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Princess Anne
- Hara OyedejiOwings Mills$780K
- Ilya RozenbergGlen Burnie$572K
- Michelle WilliamsColumbia$158K
- Kristin ClemensGaithersburg$36K
- Antonio HeroldHavre de Grace$23K
- Paul KlaverweidenFruitland$17K
- Margaret WebbAberdeen$16K
- Susan KrausTowson$16K
- Anyinke AtabongRockville$15K
- Zenatsehay GebretsadikColumbia$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.